Arvinas Inc
(NAS:ARVN)
$
34.86
-0.37 (-1.05%)
Market Cap: 2.39 Bil
Enterprise Value: 1.24 Bil
PE Ratio: 0
PB Ratio: 3.90
GF Score: 65/100 Arvinas Inc at Cowen Health Care Conference (Virtual) Transcript
Mar 07, 2022 / 02:10PM GMT
Release Date Price:
$61.23
(-5.13%)
Tyler Van Buren
Cowen and Company, LLC - Analyst
Great. Good morning, everyone. Welcome to the first day of Cowen's 42nd annual healthcare conference. My name is Tyler Van Buren. I'm a senior biotech analyst at Cowen. For this session, we will fireside chat with Arvinas. It is my pleasure to introduce Ian Taylor, the Chief Scientific Officer. Ian, thank you very much for being here with us.
Ian Taylor
Arvinas, Inc - Chief Scientific Officer
It's my pleasure, Tyler. Thanks very much for your invitation.
Tyler Van Buren
Cowen and Company, LLC - Analyst
Sure. (Conference Instructions) So with that, we'll go ahead and get started with the lead program, ER degrader, ARV-471.
Questions & Answers
Tyler Van Buren
Cowen and Company, LLC - Analyst
So Ian, the latest update on the Phase 1 dose escalation study at San Antonio Breast showed consistently strong efficacy data in two times the number of patients, and a 40% clinical benefit rate. So with the expansion
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot